Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of propofol, dexmedetomidine, and sevoflurane for organ protection during hepatectomy with or without inflow occlusion in patients with hepatocellular carcinoma and cirrhosis
ChiCTR-TRC-11001530Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of propofol, dexmedetomidine and sevoflurane in hepatocellular carcinoma (HCC) and Cirrhosis (6 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Cardiac, liver, renal, intestinal barrier, immune, and inflammatory blood biomarkers and Liver tissue pathology and apoptosis markers. Started Jan 2011; status: completed.
02
Drugs
propofoldexmedetomidinesevoflurane
03
Conditions
hepatocellular carcinoma (HCC)Cirrhosis
Beyond the preview
Go deeper on ChiCTR-TRC-11001530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001530.